Characteristics | N° (range) | (%) |
Total patients | 35 | 100 |
Age, years mean (range) | 70 (18–87) | |
Histotype | ||
Squamous | 35 | 100 |
Grading (G) | ||
G2 | 28 | 80 |
G3 | 7 | 20 |
Depth of invasion | ||
<5 mm | 5 | 14.3 |
>5 mm | 30 | 85.7 |
Margin status | ||
Negative | 18 | 51.4 |
Close | 14 | 40 |
R1 | 3 | 8.6 |
Tumor size | ||
<4 cm | 16 | 45.7 |
>4 cm | 19 | 54.3 |
Tumor stage | ||
pT1a | 4 | 11.4 |
pT1b | 29 | 82.9 |
pT2 | 2 | 5.7 |
Nodal stage | ||
pNx (cN0) | 1 | 2.8 |
pN0 | 10 | 28.6 |
pN1a | 7 | 20 |
pN1b | 12 | 34.3 |
pN2b | 5 | 14.3 |
FIGO stage (2009) | ||
Stage IA | 2 | 5.7 |
Stage IB | 7 | 20 |
Stage II | 2 | 5.7 |
Stage IIIA | 19 | 54.3 |
Stage IIIB | 5 | 14.3 |
Vulvar surgery | ||
Partial vulvectomy | 13 | 37.1 |
Radical vulvectomy | 22 | 62.9 |
Nodal surgery | ||
Monolateral procedures | 5 | 14.3 |
Bilateral procedures | 30 | 85.7 |
Median removed nodes n° | 15 (5–48) | |
Concomitant chemotherapy | ||
Cisplatin 20 mg/m2 day 1–4 plus 5-Fluorouracil 1000 mg/m2/die in continuous infusion day 1–4 (PlaFuR) | 13 | 37.1 |
Cisplatin 40 mg/m2 weekly | 3 | 8.6 |
FIGO, International Federation of Gynecology and Obstetrics.